The emergence of novel and evolving variants of SARS-CoV-2 has fostered the need for
change in the form of newer and more adaptive diagnostic methods for the detection of …

Respiratory syncytial virus is the second most common cause of infant mortality and a major
cause of morbidity and mortality in older adults (aged> 60 years). Efforts to develop a …

Background Respiratory syncytial virus (RSV) can cause serious lower respiratory tract
disease in older adults, but no licensed RSV vaccine currently exists. An adenovirus …

Background Older adults (aged≥ 70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …

Background This background document was prepared by the Strategic Advisory Group of
Experts (SAGE) on Immunization Working Group on COVID-19 Vaccines to inform the …

More than 190 vaccines are currently in development to prevent infection by the novel
severe acute respiratory syndrome coronavirus 2. Animal studies suggest that while …

Abstract Background The Ad26. COV2. S vaccine is a recombinant, replication-incompetent
human adenovirus type 26 vector encoding full-length severe acute respiratory syndrome …

Background Efficacious vaccines are urgently needed to contain the ongoing coronavirus
disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome …

The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
elicited an equally rapid response aiming to develop a COVID-19 vaccine. These efforts are …

Background The aim of this study was to investigate safety and immunogenicity of vaccine
formulations against respiratory syncytial virus (RSV) containing the stabilized prefusion …